RxDoctor Payments Data

John Capitanelli, MD

Cardiovascular Disease · West Paterson, NJNPI 1538182688

Payments from drug & device makers

$14,990in general payments, 2019–2025

Across 73 payments — averaging $205.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$14K
  • Novartis$222
  • Medtronic$208
  • Amgen$156
  • Johnson & Johnson$118
  • Pfizer$114
  • plus $378 from 12 others

What the payments were for

  • Consulting fees$5,75038%
  • Travel & lodging$2,04514%
  • Food & beverage$1,45410%
  • Education$4,10027%
  • Other$1,64011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,990 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$197,500
Medicare patients
385
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$82,834
XareltoRivaroxaban33$29,793
EntrestoSacubitril/Valsartan25$28,723
BrilintaTicagrelor15$11,836
Praluent PenAlirocumab16$8,623
ClopidogrelClopidogrel Bisulfate110$1,512
Metoprolol Succinate85$1,394
Labetalol Hcl40$1,308
SotalolSotalol Hcl37$823
Atorvastatin Calcium85$765
Rosuvastatin Calcium81$730
Losartan Potassium55$630
Carvedilol36$541
Lisinopril60$475
Ezetimibe16$412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$82,83486 claims
Johnson & JohnsonXarelto$118$29,79333 claims
NovartisEntresto$222$28,72325 claims
AstraZenecaBrilinta$75$11,83615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in West Paterson

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →